论文部分内容阅读
目的 观察氨磷汀 (am ifostine)的安全性及减少头颈部肿瘤放射治疗中的唾液腺损伤等副作用 ;观察氨磷汀与放射治疗联合应用时对头颈部肿瘤治疗效果的影响。方法 31例鼻咽癌患者 ,随机分为两组 ,均予 6 MVX线照射 ,DT6 8- 72 Gy,在每日照射前 30分钟内予氨磷汀 A(试验组 )或 B(对照组 ) 2 0 0 mg/m2 ;观察两组患者放疗前后唾液量的变化 ,严重毒性反应发生率 ,两组患者放疗的有效率。结果 试验组的唾液量下降幅度较对照组小 ,试验组的平均唾液量明显多于对照组 ,均有统计学意义 ,P<0 .0 5。放射性粘膜炎试验组比对照组明显减少 ,有统计学差异。氨磷汀应用后 ,对血色素、白细胞、血小板及肝肾功能均无明显影响 ,但恶心、呕吐反应明显增加。结论 氨磷汀能保护鼻咽癌放疗患者的唾液腺 ,明显改善口干 ,同时并未降低近期肿瘤的消退率 ,对肿瘤无保护作用 ;但消化道反应有一定增加
Objective To observe the safety of amifostine and reduce the side effects of salivary gland injury during radiotherapy of head and neck cancer. To observe the effect of amifostine and radiotherapy on the treatment of head and neck cancer. Methods Thirty-one patients with nasopharyngeal carcinoma were randomly divided into two groups, each of which was exposed to 6 MVX radiation and DT6 8-72 Gy. Patients were given amifostine A (experimental group) or B (control group) within 30 minutes before daily irradiation. 2 0 0 mg / m2. The changes of saliva before and after radiotherapy, the incidence of serious toxic reaction and the radiotherapy efficiency in both groups were observed. Results The drop of saliva volume in the experimental group was smaller than that in the control group. The average saliva volume in the experimental group was significantly more than that in the control group, both of which were statistically significant (P <0.05). Radiation mucositis experimental group significantly reduced compared with the control group, with statistical differences. Amifostine application, no significant effect on hemoglobin, white blood cells, platelets and liver and kidney function, but nausea, vomiting increased significantly. Conclusion Amifostine can protect the salivary gland of patients with radiotherapy of nasopharyngeal carcinoma and improve the dry mouth significantly without reducing the rate of recent tumor regression without any protective effect on the tumor. However, there is a certain increase in gastrointestinal reaction